Detailed cognitive function and use of drugs with anticholinergic properties in older people: A community-based cross-sectional study

Drugs and Aging

Volumn 30, Issue 3, 2013, Pages 177-182

  Uusvaara, Juho ^a,b,c   Pitkala, Kaisu H ^a,b   Kautiainen, Hannu ^a,b   Tilvis, Reijo S ^a   Strandberg, Timo E ^b,d  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Kauniala Hospital for Disabled War Veterans   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; CAPTOPRIL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLIDINIUM BROMIDE; CODEINE; CORTICOSTEROID; DIAZEPAM; DIGOXIN; DIPYRIDAMOLE; DISOPYRAMIDE; DOXEPIN; EMEPRONIUM BROMIDE; FUROSEMIDE; HYDROXYZINE; IPRATROPIUM BROMIDE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LEVOMEPROMAZINE; METOCLOPRAMIDE; NIFEDIPINE; ORPHENADRINE; OXYBUTYNIN; PERICIAZINE; PROCHLORPERAZINE; QUINIDINE; RANITIDINE; THEOPHYLLINE; TOLTERODINE; UNINDEXED DRUG;

AGED; ANTICHOLINERGIC EFFECT; ARTICLE; ATHEROSCLEROSIS; COGNITION; COGNITIVE DEFECT; DRUG USE; FEMALE; FINLAND; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; SPEECH ARTICULATION; TASK PERFORMANCE; VERBAL COMMUNICATION;

EID: 84876947739     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0055-2     Document Type: Article

References (45)

1. Ott A, Bertelera MM, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ. 1995;310(6985):970-3.
2. Pitkälä KH, Strandberg TE, Tilvis RS. Is it possible to reduce polypharmacy in the elderly? Drugs Aging. 2001;18(2):143-9.
3. Lechevallier-Michel N, Molimard M, Dartigues JF, et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol. 2005;59(2):143-51. (Pubitemid 40208849)
4. Ancelin M, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332(7539):455-9. (Pubitemid 43342043)
5. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345-51.
6. Tune L, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry. 1992;149(10):1393-4.
7. Uusvaara J, Pitkala KH, Tienari PJ, et al. Association between anticholinergic drugs and apolipoprotein E ε4 allele and poorer cognitive function in older cardiovascular patients: a cross-sectional study. J Am Geriatr Soc. 2009;57(3):427-31.
8. Carrière I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med. 2009;169(14):1317-24.
9. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39(9):1159-65. (Pubitemid 19239715)
10. Sotaniemi M, Pulliainen V, Hokkanen L, et al. CERAD-neuropsychological battery in screening mild Alzheimer's disease. Acta Neurol Scand. 2012;125:16-23.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.
12. Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults. Arch Gen Psychiatry. 2003;60:198-203. (Pubitemid 36173127)
13. Brébion G, Bressan RA, Amador X, et al. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol Med. 2004;34(2):369-74. (Pubitemid 38239645)
14. Bottiggi KA, Salazar JC, Yu L, et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry. 2006;14(11):980-4. (Pubitemid 44706417)
15. Cao YJ, Mager DE, Simonsick EM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives and ACE inhibitors in older women. Clin Pharmacol Ther. 2008;83(3):422-9. (Pubitemid 351272629)
16. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc. 2008;56(12):2203-10.
17. Cancelli I, Gigli GL, Piani A, et al. Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: a population-based study. J Clin Psychopharmacol. 2008;28(6):654-9.
18. Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225-33.
19. Strandberg TE, Pitkala KH, Berglind S, et al. Multifactorial cardiovascular disease prevention in patients aged 75 and older: a randomized controlled trial: Drugs and Evidence Based Treatment in the Elderly (DEBATE) Study. Am Heart J. 2001;142(2):945-51. (Pubitemid 33131800)
20. Strandberg TE, Pitkala KH, Berglind S, et al. Possibilities of multifactorial cardiovascular disease prevention in patients aged 75 and older: a randomized, controlled trial. Drugs and Evidence-Based Treatment in the Elderly (DEBATE) Study. Eur Heart J. 2003;24(13):1216-22. (Pubitemid 36834638)
21. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991;337(8750):1158-9.
22. Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry. 2004;75(1):61-71. (Pubitemid 38091270)
23. Salthouse TA. Relations between cognitive abilities and measures of executive functioning. Neuropsychology. 2005;19(4):532-45. (Pubitemid 41077135)
24. Bentham PW, Jones S, Hodges JR. A comparison of semantic memory in vascular dementia and dementia of Alzheimer's type. Int J Geriatr Psychiatry. 1997;12(5):575-80. (Pubitemid 27239062)
25. Mack WJ, Freed DM, Williams BW, et al. Boston Naming Test: shortened versions for use in Alzheimer's disease. J Gerontol. 1992;47(3):154-8.
26. Vogel A, Gade A, Stokholm J, Waldemar G. Semantic memory impairment in the earliest phases of Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;19(2-3):75-81. (Pubitemid 40868031)
27. Greene JD, Baddley AD, Hodges JR. Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. Neuropsychologia. 1996;34(6):537-51. (Pubitemid 26154491)
28. Budson AE, Wolk DA, Chong H, et al. Episodic memory in Alzheimer's disease: separating response bias from discrimination. Neuropsychologia. 2006;44(12):2222-32. (Pubitemid 44062596)
29. Ravens J. Vascular changes in human senile brain. Adv Neurol. 1978;20:487-501.
30. Abbott N, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41-53. (Pubitemid 41828930)
31. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000;93:457-62.
32. Beers MH, Ouslander JG, Rollinger I, et al. Explicit criteria for determining potentially inappropriate medication use in nursing home residents. Arch Intern Med. 1991;151:1825-32.
33. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arc Intern Med. 1997;157:1531-6. (Pubitemid 27305197)
34. Chutka D, Takahashi P, Hoel R. Inappropriate medications for elderly patients. Mayo Clin Proc. 2004;79:122-39. (Pubitemid 38018592)
35. Herbison P, Hay-Smith J, Ellis G, et al. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003;326:841-4. (Pubitemid 36461413)
36. Liu H, Farley J. Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacol. 2005;5:8. (Pubitemid 41460678)
37. DeMaagd G, Geibig J. An overview of overactive bladder and its pharmacological management with a focus on anticholinergic drugs. P&T. 2006;31:462-71.
38. Seale P. Anticholinergic bronchodilatators. Aust Prescr. 2003;26:33-5.
39. Tandon R, Taylor S, Quardo J, et al. The cholinergic system in schizophrenia reconsidered: anticholinergic modulation of sleep and symptom profiles. Neuropsychopharmacology. 1999;21:189-202.
40. Shiraishi M, Minami K, Uezono Y, et al. Inhibition by tramadol of muscarinic receptor-induced responses in cultured adrenal medullary cells and in xenopus laevis oocytes. JPET. 2001;299:255-60. (Pubitemid 32905142)
41. Saito M, Shibata O, Yamaguchi M, et al. Metoclopramide causes airway smooth muscle relaxation through inhibition of muscarinic M3 receptor in the rat trachea. Anesth Analg. 2004;98:325-9.
42. Isah A, Rawlins M, Bateman D. The pharmacokinetics and effects of prochlorperazine in elderly female volunteers. Oxf J. 1991;21:27-31.
43. Kay G, Abou-Donia M, Messer W, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. JAGS. 2005;53:2195-201. (Pubitemid 43001205)
44. Cechin EM, Quevedo J, Barichello T, et al. Dose-related effects of propericiazine in rats. Braz J Med Biol Res. 2003;36:227-31. (Pubitemid 36285066)
45. Minami K, Yasuhito U, Yoichi U. Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J Pharmacol Sci. 2007;103:253-60. (Pubitemid 46465767)